Good morning, welcome to the Aflac Incorporated Q2 2023 earnings call. All participants will be in a listen-only mode, should you need any assistance on the call today, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad, to withdraw a question, please press star, then two. Please note that this event is being recorded today. I would now like to turn the conference over to David Young, Vice President of Investor Relations. Please go ahead. Thank you, Jeb. Good morning, and welcome. This morning, we will be hearing remarks about the quarter related to our operations in Japan and the United States from Dan Amos, Chairman and CEO of Aflac Incorporated. Frederick Crawford, President and COO of Aflac Incorporated, will touch briefly on conditions in the quarter and discuss key initiatives, and Brad Dyslin, Global Chief Investment Officer, President of Aflac Global Investments, will provide an update on the investments. Yesterday, after the close, we posted our earnings release and financial supplement to investors.aflac.com. We also posted under Financials on the same site, updated slides of investment details related to our commercial real estate and middle market loans. In addition, Max Brodén, Executive Vice President and CFO of Aflac Incorporated, provided his quarterly video update, addressing our financial results in current capital and liquidity. Max will also be joining us for the Q&A segment of this call, along with the following members of our executive management in the U.S.: Virgil Miller, President of Aflac U.S., Al Ruggieri, Global Chief Risk Officer and Chief Actuary, June Howard, Chief Accounting Officer, and Steve Beaver, CFO of Aflac U.S. We are also joined by members of our executive management team from Aflac Life Insurance Japan. Charles Lake, Chairman and Representative Director, President of Aflac International, Masatoshi Koide, President and Representative Director, Todd Daniels, Director and CFO, Koichiro Yoshizumi, Executive Vice President and Director of Sales and Marketing and Alliance Strategy. Before we begin, some statements in this teleconference are forward-looking within the meaning of federal securities laws. Although we believe these statements are reasonable, we can give no assurance that they will prove to be accurate because they are prospective in nature. Actual results could differ materially from those we discuss today. We encourage you to look at our annual report on Form 10-K for some of the various risk factors that could materially impact our results. As I mentioned earlier, the earnings release is available on investors.aflac.com and includes reconciliations of certain non-U.S. GAAP measures. I'll now hand the call over to Dan. Dan? Thank you, David. Good morning. Glad you joined us. Reflecting on the Q2 of 2023, our management team, employees, and sales distribution have continued to work tirelessly as dedicated stewards of our business. This has allowed us to be there for the policyholders when they need us most, just as we promised. Aflac Incorporated delivered very strong earnings for both the quarter and the first six months. We remain actively focused on numerous initiatives in the United States and Japan around new products, distribution strategies to set the stage for future growth. Looking at the operation in Japan, we have continued our rollout of our WINGS cancer insurance and refreshed WAYS in Child Endowment policies. By introducing new refreshed products, we position our distribution channels for success as Japan makes great strides in recovering from the pandemic. I am very pleased with our new sales premium increase of a 26.6% increase in Japan. This reflects a 60% increase in cancer insurance sales versus the Q2 of 2022, and a significant contributor from Japan Post Company and Japan Post Insurance, which began selling our new cancer product in early April. I'm also pleased to see improvements in our sales through agencies and our other strategic alliance, Daido Life and Dai-ichi Life. We also continue to gain new customers through WAYS and Child Endowment, while also increasing opportunities to sell our third sector products, which Fred will address in a moment. Thus far, our product strategy has served us well, and I'm encouraged by our progress as we prepare for the anticipated mid-September launch of our new medical products. In addition to our products, we know how important it is for us to be where the customers want to buy insurance. Our extensive network of distribution channels, including agencies, alliance partners, and banks, allow us more opportunities to help provide financial protection to Japanese consumers as we are working hard to support each channel. Turning to the U.S., I remain encouraged by the continued productivity improvements of our agents and the contribution from growth initiatives. We continue to see success in our efforts to reengage our veteran associates. At the same time, we're seeing strong growth through brokers. I'm very excited at our Cancer Protection Assurance policy, which provides enhanced benefits at no additional cost. We know that when people experience the value of our products, it increases persistency, which benefits our policyholders and lowers our expenses. I believe that the need for the products and solutions we offer is as strong or stronger than it's ever been before in both Japan and the United States. We are leveraging every opportunity and avenue to share this message with consumers. As always, we are committed to prudent liquidity and capital management. We continue to generate strong investment results while remaining in a defensive position as we monitor evolving economic conditions. In addition, we have taken proactive steps in recent years to defend cash flow and deployable capital against a weakening yen. We remain committed to extending our track record of annual dividend increases, supported by the strength of our capital and cash flows. At the same time, we remain in the market repurchasing shares with a tactical approach, focused on integrating the growth investments we have made in our platform to improve our strength and leadership position. Overall, I think we can say that it's been a very strong quarter, especially with a vast number of factors that are in our favor. Aflac Japan had a strong quarter of sales as we executed product and distribution strategy. Aflac U.S. continued to build on its momentum as it nears pre-pandemic sales levels. Pre-tax profit margins remained very strong in Japan at 30.4% and in the U.S. at 22.2%. Plus, our capital ratios remain very strong, and our quarterly share repurchase was, like last quarter, one of the biggest in the company's history. With that, I'll turn the program over to Fred. Fred? Thank you, Dan. Let me begin by briefly commenting on conditions in Japan. As Dan commented on, our revised cancer product, which we refer to as WINGS, is doing well, now introduced in the Japan Post Group. Having rolled out WINGS in Japan Post, we are now at full strength with this refreshed product in all channels. Our entire cancer platform, including in-force policyholders, is now supported by our Yoriso Cancer Consultation Services. This platform provides concierge care to cancer policyholders, connecting them with non-insurance services. In dialogue with key alliance and distribution partners, we continue to receive feedback that this platform is a differentiator in the marketplace. From a data perspective, our market research has shown a positive and meaningful impact to our Net Promoter Score. The sale of WAYS and Child Endowment continues to deliver on our strategy of attracting younger and new policyholders, along with cross-sell performance. Since the launch of our refreshed WAYS product, approximately 80% of sales are to younger customers below the age of 50. This cohort of younger buyers has driven a concurrent third sector sales rate of approximately 50%. Looking forward, we anticipate launching our new medical product mid-September. As mentioned last quarter, this product design has been simplified to appeal to both younger policyholders with basic needs and older or existing policyholders who desire upgrading coverage. As we move through the natural product renewal cycles, we believe simplifying our products is key to driving sales productivity, attracting new and younger policyholders, and lowering our operating costs. Turning to operations, we are pleased with our expense ratio, traveling below 20% in the H1 of the year and in the face of continued revenue pressure. We are actively working to increase digital adoption, focused on new business applications, customer self-service, and claims. As we look forward, we anticipate increased levels of investment to drive digital adoption, with the goal of remaining competitive by lowering our long-term operating expenses on a per-policy basis. Turning to the U.S., our Q2 results followed a similar pattern as the Q1, with individual, dental and vision, group life and disability, and consumer markets all contributing to sales growth. Group voluntary sales has been down modestly from a strong 2022. However, we remain encouraged by the level of quoting activity that we believe positions us for a stronger H2 of the year. Our growth platforms of dental and vision, group life and disability, and consumer markets are beginning to have a more material impact on performance. In aggregate, sales produced by these platforms are up over 50%, albeit off a smaller and building base. With the build largely behind us, we are focused on driving scale, stabilizing new platforms, and leveraging our ability to bundle core voluntary products as we work with brokers on larger groups. We are absorbing a pace of investment in growth platforms that pressures our expense ratio, but naturally precedes revenue development. This is particularly the case in our group life and disability business, which is more capital intensive. As we settle into operating these platforms, we are also refining our approach to drive expense efficiencies and a long-term path to profitability. In some cases, making decisions around business we choose to exit and opportunities we aggressively pursue. Last quarter, we commented on our renewed focus on product development in the U.S. Our refreshed cancer product is up roughly 23% and still in the early stages of rollout. Of all the critical illnesses, cancer remains the most frequent and devastating to families and their financial security, and we have high expectations for this product. Last week, we announced a new group voluntary term life product, which is part of an important effort to increase our overall worksite life sales. We have lagged in terms of life sales and see this product line as an area where we have market share opportunity. Like cancer insurance, this is a product that should contribute to improved persistency. We are pleased to see a return to earned premium growth in the U.S. and modest recovery in persistency. We continue to drive utilization through wellness campaigns and benefit endorsements to in-force policies, with the objective of improved sales, persistency, and driving core revenue growth. Now let me pause, and I'm going to turn the call over to Brad Dyslin to bring you current on the health of our investment portfolio with a focus on the loan book. Brad? Thank you, Fred. During last quarter's call, we provided an update on our loan portfolios with a special focus on our middle market direct lending and real estate mortgage holdings. I am pleased to report that both of these portfolios continue to perform in line with the expectations we shared last quarter. Let me start with commercial real estate. As a reminder, most of our exposure is to transitional properties, where we make short-term floating rate loans to facilitate the asset's repositioning in the local market. TRE comprises $6.4 billion, or about 3/4 of our total $8.1 billion commercial mortgage loan portfolio, with the balance held in more traditional, longer-term fixed-rate loans. Our commercial real estate loan watch list has remained constant at approximately $900 million and consists almost entirely of TRE office properties. The workout process for these loans is complex, and negotiations with the property's owner tend to be very fluid, a dynamic we follow very closely. As a result, our foreclosure watch list gets updated relatively frequently as negotiations with the property owner ebb and flow. However, the total value of these loans has also remained relatively stable, with only a modest increase from Q1. As we mentioned last quarter, when a loan foreclosure is likely to occur, we must mark the carrying value of our loan to the fair market value of the underlying property assets. With our average loan-to-value of 65%, this accounting process resulted in a small $11 million of additional reserves in the quarter. This brings the total amount of additional reserves recognized in the H1 of the year to $21 million, which represents about 26 basis points of our $8.1 billion total commercial real estate portfolio and is the result of property value declines generally in the range of 25%-40%. Price drops that are in line with those of the financial crisis. If you simply apply a 40% price decline across our entire $900 million watch list, we would expect very manageable additional reserves of $50 million. Once a property goes into foreclosure proceedings, we no longer accrue interest on the loan, but instead realize the net operating income from the property. Given the transitional nature of these properties, we will see a decline in net investment income from this change. When considering overall investment performance, we do not expect this to have a material impact to enterprise MII. While we are not immune from the industry pressure in commercial real estate, we remain confident in the quality of the properties supporting our loans. Our strong capital position and ample liquidity allow us to be a patient investor as we manage through the downturn to maximize our overall economics. I am pleased to report our portfolio of loans to middle market companies continues to perform well and is exceeding our expectations for credit losses at this point in the cycle. Recall, this is our primary outlet for below investment grade exposure and was purposely built with a quality bias to perform well during difficult periods for credit. Our strategy of allowing only modest levels of first lien leverage on growing companies in non-cyclical industries owned by supportive sponsors is delivering strong risk-adjusted returns. Finally, you may have seen the announcement last month that Varagon Capital is being acquired by Man Group, a leading U.K. alternative asset manager. As part of this transaction, as was announced, we are exiting our equity position in Varagon, but will remain a major client. We generated strong returns on this strategic investment, realizing over three times our invested capital, in addition to solid performance on the $3 billion of middle market loans Varagon has managed for us the last 3+ years. Varagon has proven to be a great partner and terrific investor, and we are excited about their future as part of the Man Group. Our relationship with Varagon and our other current strategic equity partners is a valuable part of our strategy for accessing certain specialized private asset classes that have a strategic role in our portfolio. We continue to invest significant amounts in these high value-add forms of private credit. We look forward to continuing to execute on this strategy and creating additional value through an ownership presence in these important asset classes. Let me turn it back to Fred. Thank you, Brad. As Brad noted, we followed a disciplined approach that began with building out our external manager program, then matured into taking a minority interest in select managers. These investments have produced strong returns, and we intend to expand upon this strategy as opportunities present themselves. Market conditions remain volatile as both the U.S. and Japan economies go through a period of transition. Last week featured moves by both the Fed and the BOJ. The U.S. is looking to calm down inflation and avoid recession, while Japan continues to maintain its ultra-loose monetary policy as economic and inflationary uncertainty remain high. As Max noted in his recorded comments, through investment strategy, hedging, and capital engineering, we have greatly reduced our enterprise economic exposure to movements in the yen. In addition, our low asset leverage places us in a naturally strong position to absorb weak or volatile economic conditions and maintain capital, deployment plans. I'll now turn it back to David to take us to Q&A. David? Thank you, Fred. Before we take questions, I want to ask that you please limit yourself to one initial question and a follow-up before getting back in the queue to allow other participants an opportunity to ask a question. Joe, we will now take that first question. Our first question will come from Tom Gallagher with Evercore ISI. Please go ahead. Good morning. It, it was encouraging to see the growth in Japanese sales. I guess the, the question I have related to it is two parts. One is, how do you see the contribution from Japan Post building out? Is that a continued gradual slow ramp, or do you-- are you seeing any, any signs of stronger acceleration there? I guess the follow-up is, while there were good sales, the overall top line in terms of earned premium was a bit soft. Can you talk about your expectations for earned premium and what's, what's weighing on that and not allowing the sales improvement to necessarily translate? Thanks. Let me, let me start by making just a couple comments, and then I'll hand off to some of the folks around the table to contribute. Tom, this is Fred. First, on sales results and Japan Post in the quarter. We, you know, as you may know or may remember, based on our alliance, we don't comment on some of the specific results coming out of those channels. What we certainly can say is that the launch of the cancer product in the quarter was the majority contributor to the increase in cancer sales that you saw in our results. For example, in the Q1, without being launched in Japan Post, our sales were up in cancer around 25% or so, and as Dan mentioned in his comments, in the Q2, we were up around 60%, and you can safely assume the majority contributor of that was from Japan Post. Your question then is, what about continuation? Our view is that there is still much more runway in Japan Post over the long term, predominantly as they build efficiency in their distribution channel and more and more agents take on the cancer product and begin producing. We do think that there's a continuation of upside in Japan Post. However, it is also the case that, it commonly, right when you launch the product, you'll have an immediate jump in sales in the early months, followed by a calming down. Let me just turn to Yoshizumi-san, and/or Koide-san, if they'd like to comment or add any color, beyond what I just said. Hi, Fred. [Foreign language], Yoshizumi [Foreign language]. JP [Foreign language]. Fred, thank you. This is Yoshizumi. Let me answer some your question regarding JP. JP [Foreign language] Well, let me mention about the new product launched in the Japan Post channel. The cancer product in the Japan Post channel was launched in April. Towards this April timing, we have been conducting trainings to the Japan Post Company, the postal company, as well as Japan Post Insurance since January throughout their entire nationwide post offices. [Foreign language] We do believe the steadily, stead-steady increase of sales by the Japan Post. ... has is a result of us conducting these kinds of trainings, as well as offering our support to them directly after the launch of the product. [Foreign language] Since the Q2, between Japan, the Japan Post and Aflac, we have been confirming each layer, each level of sales process at the management level, and we've been managing these processes at each level. [Foreign language] What that means is that we will try to identify where the issues are at each management level, and we are checking those items on a monthly basis, and we are also offering solutions to these issues and solving them on a monthly basis. [Foreign language] As a result of all of these, we do believe that cancer sales will gradually increase going forward as well. [Foreign language] That's all for me. Tom, your second question was related to revenue in Japan and how to think about it. Obviously, having to take into account both our reinsurance agreement and paid up policies. I'll ask Todd to address that. Yeah, real quick, I think that one thing to remember when we went to LDTI accounting, we had to move our deferred profit liability from the benefits line to the earned premium line. That's going to create a little bit of noise in that. It's not going to be as stable as it was before. As Fred said, the reinsurance transaction that we entered into at the beginning of the year, caused about JPY 8 billion reduction in earned premium in the quarter. The paid up impact is also still there, and that was, again, about JPY 8 billion. When you normalize for those two factors and considering the DPL, we're still in the right, in the middle of the range that we gave for guidance for earned premium at approximately -1.9%. Tom, I, I would just add as well, if you look at it long term, and for us to sort of get to a level where we are replacing the business that is falling off, i.e., get to an earned premium growth of zero, we need to essentially get back for all distribution channels to pre-pandemic levels in terms of production, and also have the Japan Post channel get back to a restored production level. Got you. All right. Thanks, guys. Our next question will come from Alex Scott with Goldman Sachs. Please go ahead. Hi, good morning. first one I had for you is on some of the comments that were made in the, you know, the remarks video that you all post. you know, it was mentioned that the actual to expected are continuing to run favorable, in, in what you're seeing in the claims activity and the benefit ratios. You know, I, I was just interested what the updated view is on, you know, whether that's temporary, associated with utilization levels, you know, potentially being temporary, temporarily depressed versus maybe, you know, something that you guys have just seen longer term and that you potentially need to adjust in your long-term assumptions. This is Dan. I'll, I'll kind of mention that and let the actuaries, if they want to go into more detail, Todd or whoever. It has continued to run at a lower rate than we have anticipated year after year after year. We have tried to counter that with different things, from increased benefits on certain policies, when a new one came out. For some reason, you're seeing more and more trends to do. Well, we know one, outpatient treatments and things of that nature. As we're seeing changes take place, we have to adapt accordingly. Some of the policyholders don't change over policies, and that's something that we continue to monitor and encourage people to do. If you specifically want to talk about U.S., that's a great example. The wellness benefit hadn't been used as much, so we have really encouraged that. We're seeing that improvement, and we feel like that'll be reflected in a, in a positive manner. I think, Virgil might touch on that if he's around to, to say something. Virgil? Thank you, Dan. Yes, utilization continues to be our focus in the U.S. We have launched a series of wellness campaigns, really driving our policyholders to leverage the coverage. I think Fred or Dan mentioned that we've seen over a 22% increase in wellness utilization during that time period, which started about the Q1 of the year, and we're going to continue to do that. Our main thing is to drive and demonstrate value. We know that the average American has less than $1,000 in savings out there, so there's a benefit to them to make sure they're prepared for any unexpected medical event. Also, getting regular checkups will help anyone that gets diagnosed with some catastrophic disease like cancer. It helps them, of course, be able to get the right treatment and save their lives. We're going to continue to push on that, and I expect us to see continued improvement going forward. Alex, just, just to sort of add in terms of utilization, if you think about it, U.S. is absolutely out of the pandemic now, and you should expect the utilization to sort of get back to sort of a normal level at this point. I think we're still a little bit of what we should expect, some rebound on utilization, but definitely the vast majority of the benefits that we offer should run at more normal levels at this point. What we're doing, as Dan and Virgil alluded to, we are enhancing our products for that because we have not seen utilization bounce back to pre-pandemic levels. Why is that? Well, there are some fundamental differences that have happened during the pandemic, and there's definitely less usage of emergency rooms that we see in the data, greater use of local facilities, greater use of outpatient services rather than in-hospital services. All of this leads to lower claims utilization overall for us. If you go to Japan, we continue to see the long-term trends of shorter hospitalization stays, especially as it relates to cancer. We have seen first diagnosis, i.e., diagnosis of cancer, bounce back to more normal levels, but the surgeries and hospitalization trends are still pretty muted, and we believe that that's more driven by greater use of outpatient services as well in Japan as well, because we see that increase. Overall, the net effect of this is that it leads to a lower benefit ratio overall for us if these trends continue to stay in place. Got it. Very helpful. A follow-up I had is just on Japanese interest rates. Excuse me. I was interested in just, you know, how it affects your strategy in terms of if you, if you all are thinking through different products that you may emphasize more in a higher rate environment, as well as, you know, on the investment side, choices you're making between USD investing and JPY investing? I'll let, I'll let Brad comment on the asset allocation question. I think relative to the business model, as you may know from some of our previous comments, we continue to work on what we call internally our asset formation product strategy in Japan. That's most notably surrounding the WAYS product and refreshment and refinement to the WAYS product, training and development around that product in working with customers, and then, of course, an emphasis on cross-selling. What we've also mentioned, Alex, in the past, is that not only has a recent recovery, I put recovery in quotes, of course, but recovery in rates in Japan helped with supporting those types of products. Also importantly, is building out our reinsurance strategy, because there's no question reinsurance is going to play into the long-term viability of those types of products and maintaining, economic value as a company. Yes, some rise in rates is supportive of asset formation products, and we pay attention to that. As you can see, there's a long way to go before we would characterize the rate environment as supportive of, you know, strong profitability in those products. You still need some heavy engineering, and you absolutely are in that business for the cross-sell experience and bringing younger policyholders into the fold, that we can cross-sell into the future. Brad, comments on rates? Sure. In, in terms of investment activity, the, the rise in, in yen rates is certainly welcome news. It's been a long time since we've had these kind of levels, but one of the biggest issues we face in Japan is finding attractive spread products, and that remains our biggest challenge. We continue to take advantage of those opportunities when, when we can find them. We have been relatively successful in finding yen credit, where we can get an acceptable level of pickup over JGB yields for what we think is a pretty acceptable level of risk. Although the rise in rates is definitely welcome, it still pales in comparison to what we're able to get in some of the dollar assets. We'll continue to always be active there, but you shouldn't expect to see a big wholesale change in strategy, at least not yet. Okay. Thank you. Our next question will come from Suneet Kamath with Jefferies. Please go ahead. Thanks. Good morning. I want to go back to some of the comments that you were making on utilization, both in Japan and the U.S. It seems like things are, are moving in the, in the right direction. My question is: How quickly do these benefits get reflected in your financial statements under this kind of remeasurement concept in LDTI? My thought was, historically, these impacts would take a while to kind of feather in, but I'm wondering if under LDTI, does this get reflected in your financials much faster? Yeah, Suneet, they, they definitely come into our financials faster than they've done historically, and it's because we, we run these remeasurements each quarter and reset the net premium ratio for our forward reserves. Therefore, you, you get it into the results much quicker. I guess, so where are we with that now? I mean, are we kind of... Should we expect some of these benefits that you saw here in Q2 to persist going forward, or is it more you've baked in the lower utilization trends, and so going forward, we need to see them decline even more to get incremental benefits? We true up our reserves for recent experience and to our best estimate. Then going forward, what that means is that for you to get lower reserves in the future, you need to have an improved trend. If the utilization stays at this level, our reserves are adequate. If you were to have worsening trends, the opposite would then occur. That makes sense. My follow-up is just on, on persistency in Japan. I, I just noticed it, it fell below 94%, which, you know, is something we haven't seen in a while. Just wondering if you could unpack that a little bit. Is this lapse and reissue related to the new cancer product, or is there something else going on? Thanks. I'll ask Todd to comment on it, but you pretty much answered your own question. It has a lot to do with the introduction of cancer and natural replacement activity. Todd? Yeah, thanks. I, I think that we saw a lower lapse and reissue rate during the quarter than we did Q1, and that's typical. As we launch a new product, we expect that to wane over time, with the product being launched in the Japan Post channel. We did have some lapse and reissue activity during the quarter, but it's within our expectation, and it's still running somewhere around 50%. Suneet, w hen you naturally have sales running lower than lapses, by definition, the age of the block increases. When you have an older and more mature block, yeah, you are going to get higher lapses from it as well. One, one thing that I'd really like to add when we have this conversation, particularly spending some time in Japan and with the team, is we, we proactively promote the notion of an existing policyholder with an older cancer policy replacing their policy if it's in their best interest, if it serves them economically and from a benefit and overall quality of coverage perspective. We do that because it's good for the customer, but we also do it because it brings that customer into our shops and allows for face-to-face interaction between our distribution partners and their clients, and that often leads to cross-sell, cross-sell activity with the individual, but also cross-sell activity with their family members, as the agents have a chance to engage. Please realize that we don't actually look to avoid or curtail lapse and reissue activity. It's actually part of the strategy, and it's particularly important on the cancer side, as you can imagine. To the next question. I'd, I'd like, because we have Koide here from Japan, being President of Aflac Japan, I just think it's important for him to say a couple of words because we had such a stellar performance with sales and things. Koide, would you just... I'll ask the question, tell us how things are going in Japan? Hi. I know, Aflac Japan, Koide. I know. [Foreign language] As our sales results show, the cancer insurance product that we launched newly in August last year, it's called WINGS. It's going extremely well. [Foreign language] We now sell the cancer WINGS through all channels because we had somewhat a progressive launch of this product starting August last year with our associates, and then in January this year, Daiichi Life and Bank Channel has introduced it, and then in April of this year, the Japan Post has launched this product. [Foreign language] Well, all distribution channel sales has been very active at, of surrounding this new cancer product. Because of the new product launch, it is obviously the case that things will become very active, but at the same time, the Japanese society, the economic activities have recovered during the same time. With these two factors, I think the product has been extremely well. [Foreign language] Our cancer new product competitiveness has increased as well. As Fred mentioned earlier, we now have this support service called Yoriso Cancer Consultation Service, which is somewhat of a concierge service, concierge service for our customers, and by having this integrated with our cancer product, it is also pushing the sales as well. [Foreign language] We are also preparing to launch a new medical product with very good competitiveness in September. [Foreign language] As a result of all these things that are going well, all our employees in Aflac, Japan, as well as our salespeople in our distribution channel, of all the channels, are extremely motivated to do more sales. That's all for me. Our next question will come from Wes Carmichael with Wells Fargo. Please go ahead. Hey, good morning. Hoping you could just talk a little bit about the lapse in persistency trends in Aflac U.S.? It looks like it's improving a bit, but maybe you could help us with your expectation for how that should trend from here and maybe, any impact on the expense ratios? I think that's been a little bit elevated by lapses. Thank you. Hey, this is Virgil. Let me first say that I'm pleased with the stabilization that you see that's occurring in our persistency rate. This quarter, we came in at 78.2%. It's about 10 basis points higher than last year. I mentioned in Q1, we have done quite a few conservative efforts to go after this. We have stood up what I call an office of persistency, which is really a team of data scientists that spend 24 hours a day looking at different efforts that we can really do. I think that you're going to see even more to come from that. Today, what you heard me say earlier is mainly about driving utilization. We're really pushing out campaigns with wellness. What we did in Q1 and Q2 was more of a shotgun approach, reminding everyone that has those benefits within those policies to go out and file those wellness claims. What you'll see us doing going forward now is more of a, what I would call a more strategic or surgical attack, which is around event-driven notifications. For example, if someone recently got married or they have a birthday, we're going to be reaching out then to remind them to utilize those benefits that we have. You know, overall, you saw that the persistency plus the 6.4% increase we had in U.S. sales drove to higher earned premiums for us. The earned premium rate was up about 2.2%, and that's really what's helping right now. The growth is what's helping to balance off our expense ratios. We still see, you know, higher expenses right now with our investments and our growth initiatives, but those growth initiatives did contribute about 48% growth in the Q2 toward our revenue. Let me just ask Steve Beaver, our CFO in the U.S., if he wants to comment any further. Thanks, folks. I would just add that, remember, that the activity around driving persistency takes time to emerge in that 12-month rolling metric. We do expect, like Max said in his video, to help us bend that curve and lower the expense ratio going forward. Wes, the, the impact on the Q2 expense ratio from higher-than-normal DAC monetization was about 50 basis points. Got it. Thanks. Very helpful. Then on... I just wanted to kind of clarify, maybe a follow-up to Tom's question, but on midterm premium growth in Japan, you know, I think it was impacted by, you know, 260 basis points related to the reinsurance transaction and some lapses. I just want to clarify, for the rest of 2023, do you think that roughly, you know, 6%-ish decline is reasonable for the full year, and then it kind of moves back into that 1.5% - 2.5% decline in 2024? Just wondered your thoughts around that. The impact from reinsurance will continue throughout the year, and I would expect it to be running at that level. The impact from paid up and the BPL impact, it was rather high in this quarter. It's going to be a quite a volatile number overall, but I would just note that it was, we deem it to be quite high this quarter. Thank you. Our next question will come from Jimmy Bhullar with J.P. Morgan. Please go ahead. Hey, good morning. First, just a question on the upcoming launch of the medical product in mid-September. Should we assume that going into that, sales of medical policies will be depressed as agents are sort of waiting for the new product to be rolled out, or is that already in your numbers in Q2 as well? Why don't we have our team here in Japan comment on that? Yoshizumi-san, the question is, is there a natural pullback in medical when there's anticipation of a new medical product to come later in the year? Hi, [Foreign language] I will answer the question. [Foreign language] Since we are selling our products in multi-channel, let me start out with the associates channel. In the associates channel, as we launch our medical product soon, what I need to talk about is the cancer product that we launched in August last year. Since the cancer product will have gone around a cycle of a year, that sales will go down. [Foreign language] When we look at other channels that only sell cancer products, such as the Japan Post Channel, Dai-ichi Life Channel, and Daido Life, it will not have been a year since they've launched new cancer WINGS, and there should not be any impact on medical insurance. Sorry, there should not be any impact on cancer sales from the medical launch. Let me, let me just make one comment. This, Dan, is that, anytime we come out with a new product, it always has some impact. We're taking that as being a standard no matter what. If it's a new cancer, it affects medical, if it's a new medical, it's cancer, because everyone goes to the easiest thing to sell. Something new and sparkly always looks better, so that's going to always happen. The variation can be such, but all in all, that's part of the system. That's why we're constantly having to upgrade, is because we have to show that competitors come out with new things. We have to come out with new things, but because it isn't actual expenses, but, but, fixed cost, we have to do this. Then as you think of longer term, the alliance with the Post, what's your view on the likelihood of that being expanded beyond just cancer? Or do you think it's unlikely, given that they've already got other providers for some of the other products? Well, I don't think you ever say never. You also remember that they're our largest shareholder. Those are positive things that we'll look at going forward. Fred, you got any comments? No, I agree, Dan. I think right now, what we focus on is just expanding within the line of cancer. Meaning, so when looking at refreshing our cancer product, we also have Lump Sum Critical Illness that we include. We also have, as I, as I mentioned earlier, this URISU Cancer Consultation Services. Quite honestly, what we're focusing on now with Japan Post is not just cancer sales, but how do we expand and enrich the overall activity within that cancer line of business. I think what you can assume is anything that comes out or any developments or innovation around the cancer line of business, that we will certainly deploy that within the Japan Post system. Okay, thanks. Our next question will come from Josh Shanker with Bank of America. Please go ahead. Yeah, thank you for taking my question. Looking at the turnaround in premium growth in the U.S., it's very favorable. Is there any senior management type compensation to support the turnaround growth specifically of the company? Essentially, all of both senior management and employees have incentive compensation based on earned premium. Is, is it targeted? Can you go into how that works a little bit? You, you, you mean in terms of specific levels? Is it above a certain target, there's a long-term compensation grant? Is it? Yeah. Is there, is there a trajectory? How, how should we think about, how, how invested the company is in growing premium? In the short term, it's outlined in our proxy. You can see our MIP targets there. Okay. That's true for both the Japan business and the U.S. business? That is correct. Okay, thank you. Yeah. We try our best to keep these tied together to our bonuses, to where when you're happy, we're happy, or we're happy, you're happy. The state, if you look at those, you will see that that's a very important part of our board function under the Compensation Committee, that we tie that together. Yeah. Yeah, you'll see very clearly in each segment, U.S. and Japan, there's both sales and earned premium targets. As you can imagine, we cascade that down and get more particular by line of business when we get down to executives or officers that are in charge more directly to a particular line of business. The concept of earned premium is an essential piece of how we compensate. Josh, I will just remind you that the earned premium outlook that we gave for the year 2023 and 2024 is a CAGR of 3%-5% earned premium growth. Yep, I, I, I do. I'm aware of that. Thank you very much. Okay. Our next question will come from Mark Hughes with Truist Securities. Please go ahead. Hey, good morning. This is actually Maxwell Fritscher, I'm calling on behalf of Mark Hughes. Looking at the total recruited agent count, it looks like it reduced 4% year-over-year, on a tough comp, though, and up 6% sequentially. I was just wondering, if you could give me, you know, an outlook or what the environment looks like for recruiting and the labor market right now. Hey, this is Virgil from the U.S. Actually, I would tell you, I'm sitting very pleased with our performance for the H1 of the year. To your point, we did see a decline in the Q2, but if you look underneath some of the numbers, I look at the lead indicators, we had strong recruitment in January, February, March, April, and May. The decline really happened in June. If you look at for the first six months, though, we're sitting about 8% up. If you look at the actual career agents themselves, we had a strong increase in that Q1 at about 35%. We're, we're sitting about, and I'll be specific on a number, we got about 600 more than I really expected this time of year. What that really means to me, though, is we've got a great opportunity, which we did in June, to really push on productivity and conversions. We have first-year conversions up 5.2%, and then really driving to our average weekly producers. Our average weekly producer number is up again for the quarter, over 2%. That's really what we're trying to do. We're bringing them into the pipeline, we're getting quality recruits, we're getting them converted, we're helping to drive productivity, and then we're looking to turn them into average weekly producers. I would tell you that recruiting is favorable. For the remainder of the year, we really don't see any major headwinds out there, but we will take those recruits, convert them, and get them average weekly producers. Looking forward to a, an even stronger H2 of the year. Let me make a comment about recruiting from past. We have to remember, we're in a post-pandemic period, our track record for the past has been that with high unemployment, people tend to come selling for us because they can't get a job on a salary, so they're working on commission. That's not limited to Aflac, anybody that's in that business. Most people prefer a salary with a bonus versus all commission. That's the first point. On the other hand, when you have high unemployment, recruiting becomes more difficult. At the workplace, there are more people to enroll, so the people that are selling are seeing more people at the work site. It will be interesting what happens here as we see more people working from home. We're seeing that there. I was in a restaurant the other day, that it was closed for lunch because they couldn't get enough people to work there. These things are happening, and we're having to, to do that. I would say, considering that it's hard to find employees, certainly at the lower levels, it tells you that we're doing a pretty good job, and I, I give kudos to Virgil and their team for what they're doing because it is, it is a little bit uncharted waters. The tradition of the way we've been doing it, I've just got to see how it falls out. I want to make that comment. Yeah. To that, to that point, Dan, I, we had that baked in our numbers. That's what I mean when I say we're on target with our expectations. I mentioned in Q1, you won't see these, these humongous numbers what you see in the past, right? We, we've got... That's why the, you see, a conservative effort on making sure we convert who we have, and it's, it's going pretty well for us this year. If we could for a minute before we go to the next question. Jimmy had asked a question earlier about our expansion opportunities in Japan Post, as Dan mentioned, our President, Koide-san, is here with us today, this morning in Columbus, and he would like to add just a few comments about the Japan Post alliance. Koide-san? Hi, Aflac Japan, Koide. [Foreign language] So, this is Koide once again. Let me just add a little bit on what we are doing or with the Japan Post Group or the Japan Post Insurance. We are actually doing a lot of collaboration in various areas. For example, apart from the cancer insurance sales, we are also working with the Japan Post Insurance Group to have concierge service on nursing care area. On top of that, we are also doing some startup acceleration program together with the Japan Post Insurance Group. As you can see, we are working with the Japan Post Group, outside of cancer insurance area as well. That's all. Thank you. All right, Joe, I believe that's the- This concludes our question and answer session. I'd like to turn the conference back over to David Young for any closing remarks. Thank you, Joe. that, that concludes our call. I want to thank you all for joining us this morning. Please reach out to the investor relations team if you have any questions, and we look forward to speaking with you soon and wish you all continued good health. Thank you. The conference has now concluded. Thank you very much for attending today's presentation. You may now disconnect your lines.